−1.59USD
−30.04 MUSD
57.42 M
About Regulus Therapeutics Inc.
Sector
CEO
Joseph P. Hagan
Headquarters
San Diego
Website
Employees (FY)
30
Founded
2007
ISIN
US75915K3095
FIGI
BBG000R33DR2
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RGLS is 2.22 USD — it has decreased by 5.13% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Regulus Therapeutics Inc. stocks are traded under the ticker RGLS.
Regulus Therapeutics Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
RGLS stock is 8.94% volatile and has beta coefficient of 1.21. Check out the list of the most volatile stocks — is Regulus Therapeutics Inc. there?
One year price forecast for Regulus Therapeutics Inc. has a max estimate of 11.00 USD and a min estimate of 3.00 USD.
RGLS earnings for the last quarter are −0.40 USD whereas the estimation was −0.40 USD which accounts for −0.84% surprise. Estimated earnings for the next quarter are −0.40 USD. See more details about Regulus Therapeutics Inc. earnings.
Regulus Therapeutics Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 6.00 K USD.
Yes, you can track Regulus Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
RGLS stock has fallen by 15.59% compared to the previous week, the month change is a 6.33% fall, over the last year Regulus Therapeutics Inc. has showed a 77.60% increase.
RGLS net income for the last quarter is −8.06 M USD, while the quarter before that showed −7.82 M USD of net income which accounts for −3.03% change. Track more Regulus Therapeutics Inc. financial stats to get the full picture.
Today Regulus Therapeutics Inc. has the market capitalization of 153.19 M, it has decreased by 1.84% over the last week.
No, RGLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RGLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regulus Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 30.00 employees. See our rating of the largest employees — is Regulus Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regulus Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regulus Therapeutics Inc. stock shows the sell signal. See more of Regulus Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Regulus Therapeutics Inc. future price: according to them, RGLS price has a max estimate of 11.00 USD and a min estimate of 3.00 USD. Read a more detailed Regulus Therapeutics Inc. forecast: see what analysts think of Regulus Therapeutics Inc. and suggest that you do with its stocks.